Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep20 | Adrenal cortex (to include Cushing's) | ECE2016

Congenital adrenal hyperplasia– “natural history of the disease” – very late diagnosis in a series of patients

Ambroziak Urszula , Kepczynska-Nyk Anna , Lenkiewicz-Sidor Maja , Jazdzewski Krystian , Malunowicz Ewa , Bednarczuk Tomasz

Background: Classical congenital adrenal hyperplasia (CAH) is diagnosed mainly in newborns. While patients with salt wasting form cannot survive without timely diagnosis, those with simple virilizing or nonclassical may be diagnosed even in advanced age.Aim: To present clinical, biochemical, radiological and genetic characteristics of series of CAH patients diagnosed in advanced adulthood.Material and methods: Eight patients (F=5, ...

ea0032p18 | Adrenal cortex | ECE2013

The diagnosis of nonclassical congenital adrenal hyperplasia due to 21 hydroxylase deficiency in woman can be established by genetic testing or urine steroid profile analysis but not by ACTH stimulation test

Ambroziak Urszula , Kepczynska-Nyk Anna , Nowak Karolina , Malunowicz Ewa Maria , Morawska Emilia , Kunicki Michal , Bednarczuk Tomasz

Backgroud: ACTH stimulation test is considered the basic diagnostic tool in the diagnosis of nonclassical congenital adrenal hyperplasia due to 21 hydroxylase deficiency (CAH). The cut off of 17OHP stimulation recommended for diagnosis is 10 ng/ml.Aim: To assess whether the recommended threshold of 17OHP after ACTH stimulation confirms nonclassical CAH among woman with hyperandrogenism and elevated basal 17OHP level.Material and Me...

ea0032p592 | Female reproduction | ECE2013

Overnight 1 mg dexamethasone androgen suppression test is useful diagnostic tool in hyperandrogenism.

Ambroziak Urszula , Kepczynska-Nyk Anna , Nowak Karolina , Morawska Emilia , Kunicki Michal , Bednarczuk Tomasz

Introduction: Low dose dexamethasone (DEX) androgen suppression test (LDDAST) is considered a tool to distinguish between the sources of androgen excess and to exclude/confirm autonomy of androgen overproduction.Aim: To assess whether 1 mg DST can be used instead of LDDAST.Materials and methods: Thirty-three consecutive women with hyperandrogenism age 18–38 years undergone overnight 1 mg DEX androgen suppression test and LDDAS...

ea0049gp122 | Endocrine Tumours | ECE2017

The natural history of adrenal incidentaloma – results from the international prospective multi-centre EURINE-ACT study

Bancos Irina , Chortis Vasileios , Lang Katharina , Prete Alessandro , Terzolo Massimo , Fassnacht Martin , Quinkler Marcus , Kastelan Darko , Vassiliadi Dimitra , Beuschlein Felix , Ambroziak Urszula , Sitch Alice , Deeks Jonathan , Arlt Wiebke

Background: Adrenal masses are discovered in 5% of abdominal imaging scans. Work-up aims at exclusion of malignancy and hormone excess. However, estimates of these risks derive from retrospective studies only, mostly small and with significant selection bias.Methods: Prospective multi-centre study (2011–2016) in 14 centres (11 countries) of the European Network for the Study of Adrenal Tumours (ENSAT) with prospective consecutive enrolment of patien...

ea0049ep48 | Adrenal cortex (to include Cushing's) | ECE2017

Late night salivary cortisol measurement may help in excluding Cushing’s syndrome in patients with chronic kidney disease

Ambroziak Urszula , Kondracka Agnieszka , Rojek-Trębicka Jadwiga , Gajkowski Paweł , Stańczyk Agnieszka , Stępor Malwina , Bednarczuk Tomasz

Objective: The diagnosis of Cushing’s syndrome may be challenging, especially in cases of patients with chronic kidney disease (CKD).Aim: The assessment of late night salivary cortisol concentration, serum and salivary concentration in overnight dexamethasone suppression test in patients with CKD stage III–V and a control group.Patients and methods: 37 patients mean age 66±12 (M=13) with CKD stage III–V...

ea0044oc4.6 | Adrenal and Steroids | SFEBES2016

Demographics of adrenal incidentaloma – results from an international prospective multi-centre study in 2190 patients

Bancos Irina , Chortis Vasileios , Lang Katharina , Terzolo Massimo , Fassnacht Martin , Quinkler Marcus , Kastelan Darko , Vassiliadi Dimitra , Beuschlein Felix , Ambroziak Urszula , Deeks Jonathan , Arlt Wiebke

Background: Adrenal masses are discovered in 5% of cross-sectional abdominal imaging scans. Work-up aims at exclusion of malignancy and hormone excess. However, estimates of these risks presently derive from retrospective studies only, mostly small and with significant selection bias.Methods: Prospective multi-centre study (2011–2016) in 21 centres (17 countries) of the European Network for the Study of Adrenal Tumours (ENSAT) with consecutive enrol...

ea0035p338 | Developmental Endocrinology | ECE2014

Genome-wide survey for clinically relevant structural abnormalities contributing to pathogenesis of combined pituitary hormone deficiency (CPHD) with childhood onset.

Budny Bartlomiej , Rydzanicz Malgorzata , Szymczak Klaudia , Szkudlarek Malgorzata , Wolinski Kosma , Wrotkowska Elzbieta , Baszko-Blaszyk Daria , Goleb Monika , Bednarczuk Tomasz , Ambroziak Urszula , Niedziela Marek , Obara-Moszynska Monika , Rabska Barbara , Derebecka Natalia , Bluijssen Hans , Wesoly Joanna , Ruchala Marek , Ziemnicka Katarzyna

Introduction: Combined pituitary hormone deficiency (CPHD) results in deficit of growth hormone and coexisting failure of synthesis or excretion at least another pituitary hormone. Transcription factors controlling expression of genes required for pituitary organogenesis are orchestrating entire development process and certain cell lineages differentiation, contributing therefore significantly to CPHD pathogenesis with childhood onset.Aims: The purpose o...

ea0056oc7.2 | Genomic and clinical aspects of endocrine tumours | ECE2018

Urine steroid metabolomics as a diagnostic tool for detection of adrenocortical malignancy – a prospective test validation study

Bancos Irina , Taylor Angela , Chortis Vasileios , Sitch Alice , Lang Katharina , Prete Alessandro , Terzolo Massimo , Fassnacht Martin , Quinkler Marcus , Kastelan Darko , Vassiliadi Dimitra , Beauschlein Felix , Ambroziak Urszula , Biehl Michael , Deeks Jonathan , Arlt Wiebke

Background: Adrenal masses are discovered in 5% of abdominal imaging scans. Accuracy of currently available imaging tests to diagnose malignancy is poor. In a proof-of-concept study (JCE&M 2011;96(12):3775-84), we had demonstrated 90% sensitivity and specificity in detecting adrenocortical carcinoma (ACC) for urine steroid metabolomics, the combination of mass spectrometry-based steroid profiling and machine learning-based data analysis. This diagnostic performance is supe...

ea0090oc9.3 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Prolonged exposure to target mitotane concentrations is associated with better recurrence-free survival in patients with adrenocortical carcinoma on adjuvant treatment

Puglisi Soraya , Calabrese Anna , Basile Vittoria , Kimpel Otilia , Altieri Barbara , Angelousi Anna , Kaltsas Gregory , Ambroziak Urszula , Appetecchia Marialuisa , Arosio Maura , Berruti Alfredo , Cosentini Deborah , Canu Letizia , Ceccato Filippo , Dalmazi Guido Di , Bouys Lucas , Libe Rossella , Papierska Lucyna , Pittaway James , Kienitz Tina , Quinkler Marcus , Elhassan Yasir , Ronchi Cristina , Saiegh Leonard , Stigliano Antonio , Dusek Tina , Kastelan Darko , Fassnacht Martin , Terzolo Massimo

Background: The management of adjuvant mitotane therapy in patients with adrenocortical carcinoma (ACC) is challenging. Plasma mitotane concentrations>14 mg/l have been associated with efficacy in the treatment of advanced ACC; however, data in the adjuvant setting are mixed. Moreover, there is no consensus on how to assess the optimal exposure to mitotane and all the proposed methods have inherent limitations. We have recently proposed a new method analogous to what is es...

ea0065ec1.3 | Clinical Endocrinology Trust Best Abstract Clinical | SFEBES2019

Urine steroid metabolome analysis allows for metabolic risk stratification in 1309 prospectively recruited patients with benign adrenal tumours and different degrees of cortisol excess

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urszula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe Astrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , O'Reilly Michael W , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Benign adrenal tumours (AT) can be non-functioning (NFAT) or associated with cortisol excess, as indicated by failure to suppress serum morning cortisol to <50 nmol/l in the 1mg-dexamethasone suppression test (1 mg-DST). The latter group divides into patients with clinically overt signs of cortisol excess (adrenal Cushing’s syndrome, CUSH) and patients lacking CUSH signs (mild autonomous cortisol excess, MACE). Smaller series and a recent meta-analysis rep...